MediWound (MDWD) CEO details warrants, RSUs and options in Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
MediWound Ltd. Chief Executive Officer Gonen Ofer filed an initial ownership report detailing his equity and derivative holdings in the company. The filing lists direct holdings of ordinary shares and multiple grants of restricted share units (RSUs) and stock options that vest over four-year schedules.
The report shows Series A Warrants exercisable into 8,168 ordinary shares at an exercise price of 13.4750 per share, expiring on November 28, 2026. It also outlines several stock option grants over different years, with exercise prices ranging from 11.8850 to 18.5400 per share and expirations from 2032 through 2036. Footnotes explain that both RSUs and options vest 25% after one year from grant and 6.25% each quarter over the next three years, providing long-term, performance-linked compensation rather than immediate open-market transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
11 transactions reported
Mixed
11 txns
Insider
Gonen Ofer
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Warrants | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Series A Warrants — 8,168 shares (Direct);
Stock Option (right to buy ordinary shares) — 85,714 shares (Direct);
Ordinary shares — 22,137 shares (Direct)
Footnotes (1)
- The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on June 7, 2022 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on June 7, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on May 31, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
FAQ
What does the MediWound (MDWD) Form 3 filing by CEO Gonen Ofer show?
The Form 3 shows CEO Gonen Ofer’s initial ownership in MediWound, including ordinary shares, RSUs, Series A Warrants, and several stock option grants. It establishes his existing equity-based position rather than reporting new market purchases or sales.
How are Gonen Ofer’s MediWound (MDWD) RSU grants structured?
The RSUs vest 25% on the one-year anniversary of each grant date, then 6.25% vests quarterly over the following three years. This schedule fully vests each grant on its four-year anniversary, aligning compensation with multi-year service and company performance.
What derivative securities does the MediWound (MDWD) CEO report holding?
The CEO reports Series A Warrants exercisable into 8,168 ordinary shares at 13.4750 per share, plus several stock option grants. These options have exercise prices between 11.8850 and 18.5400 and expire between 2032 and 2036.
Are there any buy or sell transactions in this MediWound (MDWD) Form 3?
No buy or sell transactions are reported. The Form 3 is an initial statement of beneficial ownership, listing existing holdings of ordinary shares, RSUs, warrants, and options without indicating new open-market purchases or sales on the reported date.
How do Gonen Ofer’s MediWound (MDWD) stock options vest over time?
Each option grant vests 25% on the first anniversary of its grant date, with the remaining 75% vesting at 6.25% per quarter over three years. This four-year vesting pattern encourages longer-term alignment between executive incentives and shareholder interests.
What is the significance of the Series A Warrants in the MediWound (MDWD) Form 3?
The Series A Warrants allow the CEO to acquire 8,168 ordinary shares at 13.4750 per share until November 28, 2026. They represent potential future share ownership if exercised, not an immediate share purchase or sale.